Catalent, Inc. (NYSE:CTLT) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 1,870,000 shares, a growth of 78.1% from the December 15th total of 1,050,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 1.6 days.
Several brokerages have recently commented on CTLT. Morgan Stanley lifted their target price on Catalent from $98.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Catalent from $91.00 to $100.00 and gave the company a “hold” rating in a research note on Thursday, November 5th. JPMorgan Chase & Co. raised their price target on shares of Catalent from $110.00 to $130.00 and gave the stock an “overweight” rating in a research report on Friday, January 8th. UBS Group lifted their price target on shares of Catalent from $105.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Finally, Argus boosted their price objective on shares of Catalent from $100.00 to $110.00 in a research report on Thursday, September 24th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Catalent presently has a consensus rating of “Buy” and a consensus price target of $110.30.
Shares of CTLT stock opened at $114.75 on Thursday. Catalent has a 1 year low of $31.04 and a 1 year high of $120.48. The firm has a market capitalization of $18.90 billion, a PE ratio of 73.09, a price-to-earnings-growth ratio of 2.61 and a beta of 1.50. The stock has a fifty day moving average of $101.82 and a two-hundred day moving average of $91.53. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.14 and a current ratio of 2.56.
In other news, SVP Steven L. Fasman sold 2,425 shares of the stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $100.99, for a total transaction of $244,900.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Aristippos Gennadios sold 13,662 shares of Catalent stock in a transaction dated Monday, December 21st. The stock was sold at an average price of $102.84, for a total value of $1,405,000.08. The disclosure for this sale can be found here. Insiders have sold a total of 19,163 shares of company stock worth $1,990,667 over the last 90 days. 1.00% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the business. HM Payson & Co. bought a new position in shares of Catalent in the third quarter valued at approximately $25,000. Paces Ferry Wealth Advisors LLC acquired a new stake in Catalent during the 3rd quarter worth about $31,000. Ellevest Inc. purchased a new stake in Catalent during the third quarter valued at about $45,000. First Horizon Advisors Inc. boosted its holdings in shares of Catalent by 120.6% in the third quarter. First Horizon Advisors Inc. now owns 556 shares of the company’s stock worth $47,000 after buying an additional 304 shares during the period. Finally, C M Bidwell & Associates Ltd. purchased a new position in shares of Catalent in the third quarter worth approximately $108,000. Institutional investors own 97.84% of the company’s stock.
Catalent Company Profile
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
Further Reading: What is Liquidity?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.